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The high frequency of the infection, commonality of the
pathogens involved, increasing occurrence of antimicro-
bial resistance, and the costs associated with managing
community-acquired pneumonia (CAP) in both in- and
out- settings, have inducedexpert committees to publish
a number of treatment guidelines intended to improve
the care of patients with CAP (1^6). In general, they all
recommend the use of second- or third-generation ce-
phalosporins in combination with a macrolide for severe
pneumonia, but for milder, ambulant or outpatient CAP,
there are important di¡erences in the details of the re-
commendations. In fact, guidelines variably include one
or more of oral aminopenicillins, tetracyclines, macro-
lides, £uoroquinolones, £ucloxacillin or streptogramins.
The di¡erences are presumably multi-factorial and at
least partly due to diversities in local health systems and
to the sources of information at the clinician’s disposal.
Local therapeutic traditions, marketing factors, and
scienti¢c rationale are probably equally important in
the choice of the treatment for CAP (7).
Appropriate application of clinical practice guidelines
involves careful monitoring to ensure improved patient
outcomes or decreased costs without adversely a¡ect-
ing patient care (8). By improving patient health out-
comes, overall costs of illnessmay be reduced, largely as
a result of a decrease in hospitalization, the most of the
costly component of healthcare for patients with CAP.
However, althoughmost of the published guidelines pro-
vide appropriate antimicrobial choices, only fewmeasure
medical outcomes or costs associated with the treat-
ment algorithms. This is in contrast with the ultimate
goal of the care of patients with CAP that is to provide
high quality of care and the best outcome at a¡ordable
prices.Received15 February 2002; accepted in revised form15 February 2002
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Simplepatientmeasurements, includingmortality, length
of hospital stay (LOS), pneumonic complications, and de-
compensation of comorbidity, are important medical
outcome indicators. Recently, Nathwani et al. (9) have
suggested to use duration of hospital stay, percentage of
patients requiring intensive care unit (ICU) admission,
30-daymortalityrate, readmissionwith an associatedill-
nesswithin 30 days of hospital discharge, and cost of care
as outcome indicators at least for hospitalized patients
with CAP. Deplorably, parameters for acceptable care
of CAP must still be validated. In any case, also in the
eventuality that outcome indicators would be used, it is
extremely di⁄cult to determine if guidelines change out-
comesbecause the e¡ect of a guideline in changing physi-
cian behaviour precludes the use of a randomized study
design inmeasuring guideline e¡ects.
IMPACTOFGUIDELINESON
CLINICALOUTCOMES
Guidelines have been developed to improve outcomes.
Unfortunately, only the e¡ects of AmericanThoracic So-
ciety (ATS) guidelines on medical outcomes, LOS, and
antimicrobial costs in the American Healthcare system
havereallybeen examined.Mostof the studies are retro-
spective andmany are of insurance databases, the valid-
ity of which may be unclear. Whether such results are
transferable to other countrieswith di¡erent healthcare
systems is unknown.Moreover, the results of these stu-
dies are rather contrasting.
Adherence to guidelines and improved
outcomes
Two published studies have addressed the issues of e⁄-
cacy and cost of treatment, and both involve CAP. The
¢rst study used the ATS guidelines for the treatment
of outpatient CAP between 1991 and 1994 (10). Of 546
206 RESPIRATORYMEDICINEpatients less than 60 years old without comorbidities,
62.1% were prescribed an antibiotic consistent with
these guidelines.The twomajor deviations from the ATS
guidelines consisted of amoxicillin, prescribed in 26.6%,
and clarithromycin monotherapy in non-smokers, pre-
scribed in16.4%. Among 318 patients older than 60 years
with comorbidities, only 17.6% were prescribed an anti-
biotic consistent with the ATS guidelines. The regimens
not consistent with ATS guidelines were erythromycin
in 50.8% and clarithromycin in 14.1%.The e⁄cacy of the
treatmentsFmeasured by hospitalization, complica-
tions, symptoms, time of return to work, and quality of
lifeFwas the same in patients prescribed regimens con-
sistent with the ATS guidelines as well as in those who
were not.The only di¡erence was cost of therapy. Out-
patients aged 60 years or younger with no comorbidity
whowereprescribed therapy consistentwithATSguide-
lines (i.e., erythromycin with some exceptions) had 3-
fold lower antimicrobial costs ($5.43 vs $18.51) andno sig-
ni¢cant di¡erences in medical outcomes. Outpatients
older than 60 years or with one comorbidity or more
whowereprescribed therapy consistentwithATSguide-
lines (i.e., second-generation cephalosporin, sulpha-
methoxazole ^trimethoprim, or b-lactam and b-
lactamase inhibitor with or without a macrolide) had
10-fold higher antimicrobial costs ($73.50 vs $7.50). De-
spite trends towards higher mortality and subsequent
hospitalization, no signi¢cant di¡erences in medical out-
comes were observed.
The second study, from the Pneumonia Patient Out-
comes ResearchTeam (PORT), assessed patterns of anti-
microbial use, costs of therapy, andmedical outcomes atTABLE 1. Costs of antimicrobial therapyby study site andmedic
UPMC
Outpatients
Preparation and dispensing 4.01
Antimicrobial agents 6.10
Total episode 10.80
Outpatients admitted to a
hospitalwithin 30 days
of presentation (%)
13.0
Inpatients
Preparation and administration
of parenteral therapy (in hospital)
103.90
Parenteral agents (inhospital) 167.90
Oral agents (in hospital) 11.70
Parenteral and/ororal agents
(upon discharge)
40.80
Total episode 315.60
Patients readmitted to the hospitalwithin
30 days of admission, (%)¢ve outpatient and institutional settings between 1991
and1994 (11). In the outpatient setting, cost of therapies
ranged from $10.80 to $58.90. Medical outcomes varied
signi¢cantly with respect to subsequent hospitalization,
which ranged from 2.2 to 22.2%.The institutionwith the
highest outpatient cost had the highest hospitalization
rate, and the institution with the lowest cost had the
lowest hospitalization rate (Table 1). Although mono-
therapy was very common in the outpatient setting,
combination therapy (a median of three drugs) was fre-
quently used in hospitals.Duration of parenteral therapy
was variable due to switches from parenteral to oral
therapy for hospitalizedpatients, which resulted in vary-
ing inpatientcosts.To account for these factors, the aver-
age daily cost of total antimicrobial therapy alone was
calculated and it ranged from $25.80 to $43.70.Themed-
ian cost of parenteral therapy alone ranged from $58.30
to $167.90.Outcomes again varied with respect to read-
mission rates, which ranged from 7.4 to14.1%.The hospi-
tals with the lowest antimicrobial costs had the lowest
readmission rates (Table1).
Both of these studies were well designed and
essentially arrived at the same conclusions. When
treating CAP, there is little di¡erence in medical out-
comes between expensive and inexpensive therapies,
providing the drug chosen covers the pathogens. How-
ever, for the algorithms towork, theymustbe cost-e¡ec-
tive, and thus the least expensive agents should be
recommended.
Other studies on the impact of CAPguidelines on clin-
ical outcomes have recently been published. However,
these studies have potential limitations because theyal outcome
Median costs by study site (in U.S.)
SFMC MGH HCHP VGH
4.01 4.01 4.01 4.01
54.90 7.70 5.40 7.40
58.90 13.50 11.10 12.90
22.2 7.9 2.2 4.7
91.30 91.30 F 91.30
99.40 58.30 F 97.70
13.80 2.80 F 4.80
31.00 12.40 F 4.20
239.00 183.70 F 228.70
14.1 F 7.4
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biases were possible.
In four ambulatory, urgent-care facilities (Instacares), a
pneumonia practice guideline including admission deci-
sion support in combination with speci¢c outpatient
antibiotic recommendations was implemented for a 12-
month period (12) (Table 2). After implementation, phy-
sicians used the pneumonia guideline form in 90% of
cases. The percentage of patients admitted within 30
days decreased from13.6 to 6.4% (P = 0.01).Only ¢ve pa-
tients before (2.5%) and three patients after (1.1%) guide-
line implementation required subsequent hospital
admission within 30 days after initial outpatient treat-
ment. Only two deaths occurred in the study cohort,
both outpatients before implementation. The positive
predictive value was 14.4%, and the negative predictive
value for admission was 98.8% after guideline implemen-
tation. Apossible explanation for the observedpredomi-
nant outpatient treatment of pneumonia is the
orientation and practice style of the physicians sta⁄ng
Instacares. The outpatient orientation of these physi-
cians, plus the capability of Instacares to administer par-
enteral antibiotics andprovide daily outpatient follow-up
care increases the likelihood of patients not being ad-
mitted. Guideline recommendation for admission was
more likely to be followed in patients withmore risk fac-
tors and hypoxaemia.
A CAP treatment guideline based on the ATS guide-
lines for the initial management of adults with CAP) sig-
ni¢cantly reduced 30-day mortality in both inpatients
and outpatients aged 65 years treated in a regional
healthcare organization, Intermountain Health Care, in
the US. After implementation of the guidelines in the
period1993^1997, 30-daymortality fromCAPwas signif-
icantly reduced among 2547 patients cared for by Inter-
mountain Health Care, when compared with 11308
patients treated elsewhere (11vs 14.2%).The proportion
of Intermountain Health Care patients treated withTABLE 2. Proportions of patients of patients admitted vsguideli
Variables
Recommended for
admission
Admitted
Not admitted
Recommended foroutpatientcare
Admitted
Not admitted
Positive predictive value %
Negative predictive value %
Sensitivity %
Speci¢city %guideline-recommended antibacterials increased from
28.1to 56.3% during the study period (13).However, phy-
sicians appropriately overrode guideline recommenda-
tions frequently, and thereby decreased the rate of
admission.
Suchyta et al. (14), in a study limited by its non-rando-
mized design, have documented that the introduction of
ATS guidelines into the outpatient setting improved the
management of patients who were presented to urgent
care centres with CAP, resulting in decreased hospital
admission rates, overall costs, and LOS, without com-
promising outcomes (Table 3). After guideline implemen-
tation, mean (7SD)) antibiotic costs per patient
decreased from1867203 to1417133, directcosts perpa-
tient decreased from 6787142 to 3197142, and costs for
inpatient care decreased from 94717541 to 50877441.
Prescription of recommended antibiotics increased from
45 to 72% after implementation of guideline.
In another study (15), empirical antimicrobial regimens
for hospitalizedpatientswith presumedCAP inU.S. hos-
pitals, including compliance with ATS guidelines have
been described and evaluated. Compliance with the
guidelines was 81% in patients with non-severe CAP.The
most common antibiotic regimen used for empiric treat-
ment was ceftriaxone alone or in combination with a
macrolide (42%).The overall mortality rate was 5.5%. A
regimen inconsistent with the ATS guidelines was signi¢-
cantly associatedwith increased LOS, whereas the addi-
tion of a macrolide to either a second-or third-
generation cephalosporin or a b-lactam/b-lactamase in-
hibitor was associatedwith decreasedmortality and re-
duced LOS. Also Stahl et al. (16) have documented that
use of macrolides, as part of an initial therapeutic regi-
men, appears to be associatedwith shorter LOS. In their
study, patients who received macrolides within the ¢rst
24h of admission had a markedly shorter LOS (2.8 days)
than those not so treated (5.3 days). This e¡ect dimin-
ished as the interval before administering macrolidesnerecommendations in four ambulatory, urgent-care facilities
Before
implementation
After
implementation
622 15
61 89
5 2
111 158
26.5 14.4
95.7 98.8
81.5 88.2
64.5 64.0
TABLE 3. E¡ects of a practice guideline for CAP in anoutpatient setting
Controlperiod Interventionperiod P
Hospitalized (%) 14 6 0.01
Length of stay (h) 1547135 89755 0.04
Antibiotic costs for patient ($) 1867203 1417133 0.009
Directcosts for patient ($) 6787142 3197142 0.008
Costs for inpatientcare ($) 94717541 50877441 0.19
FIG. 1. Adequacy of therapy according to adherence to the
therapeutic guideline.
208 RESPIRATORYMEDICINEincreased. Including ceftriaxone aspartof the initial ther-
apy did not appear to a¡ect LOS.Gleason et al. (17) have
reported the results of a population-based national
study of Medicare patients who had been hospitalized
with CAP. They observed that £uoroquinolone mono-
therapy or therapy with a macrolide combined with se-
lected second- or third-generation cephalosporins were
associated with lower mortality rates compared with
therapy with third-generation cephalosporins alone.
The reasons for improved outcomes with the addition
of a macrolide are not known, butmay be due to a num-
ber of mechanisms. Atypical pathogens, including Legio-
nella,Chlamydia, andMycoplasma account for up to 20%
ofCAPcases. It is possible that the additional coverage of
these pathogens provided by macrolides is responsible
for improved outcomes. An additional possibility for re-
duced LOS and decreased mortality associated with
macrolides may be associated with their anti-in£amma-
tory action (18). In any case, Houck et al. (19) examined
the association of empiric inpatient antibiotic treatment
of CAPwithmortality, andwhether this association var-
ies from year to year.They have reported that the addi-
tion of a macrolide to the initial empiric b-lactam
treatment of CAP patients was associated with signi¢-
cantly improved survival rates during1993.This apparent
macrolide bene¢t was greatly reduced and not statisti-
cally signi¢cant in1995 and1997, thus documenting yearly
variability in the bene¢t from such therapy, perhaps as a
result of a temporal variation in the incidence of atypical
pathogen pneumonia.
Recently,Malone and Shaban (20) haveretrospectively
reviewed outcomes of care and antibiotic utilization for
CAP throughout a group of not-for-pro¢t hospitals and
found that patientswith CAP treated inconsistentlywith
ATS guidelines had a 4.46 higher risk of inpatient mortal-
ity andhad signi¢cantly longer LOS.UsingATS guidelines,
51 out of 330 (15.5%) patients were not treated with re-
commended antimicrobial therapy.Of these patients, 14
had non-severe cases of CAP and 37 cases were severe.
Factors found tobe associatedwith in-hospitalmortality
includednon-adherence to ATS guidelines, decreased ur-
ine output, and increasing age. Signi¢cant predictors of
LOS included age, non adherence to ATS criteria, sus-
pected aspiration, discharge status, low pulse oximetry
on admission, decreased urine output, use of vasopres-sor medications, and interstitial lung disease; the most
commonly prescribed antibiotic was cefuroxime injec-
tion, representing 25% of the antibiotic orders.
Adherence to guidelines and no impact on
clinical outcomes
All these studies indicate that adherence to guidelines re-
duced LOS and decreased mortality. However, Marras
and Chan (21) were unable to demonstrate any signi¢-
cant di¡erences in mortality or length of hospitalization
depending on guidelines adherence. This was also the
case in the relatively small subset that received outpati-
ent antibiotics prior to hospital admission. Analysis of
LOS datawas also repeatedwith non-parametric testing
(Mann^Whitney U) without altering the overall conclu-
sions. Also, a more recent study (22) has con¢rmed this
¢nding. Although initial therapy was based on the thera-
peutic guideline, adherence to the guideline did not im-
prove the outcome whereas adequate therapy did. In
particular, there was no di¡erence in adherence to the
guideline when comparing survivors and non-survivors
(64 vs 65%) (Fig.1).Nevertheless, when sensitivity of the
pathogens to the therapy, instead of adherence to the
guideline,wasused forde¢ning adequacyof therapy, ade-
quate therapy was signi¢cantly more common in survi-
vors. In severe CAP, adherence to the guideline was
poor in survivors and non-survivors, as the prescribed
regimen was followed strictly in 14% and partially (lack
of coverage only for either atypical pathogens or for
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mained high, sometimes in spite of correct antibiotic
coverage. In severe CAP, other factors besides the ade-
quacy of therapymay a¡ect outcome.These results indi-
cate that adherence to the guideline does not improve
the outcome but adequate therapy does. Nevertheless,
Simpson et al. (23), who examined CAP deaths in pre-
viously ¢t young adults in England and Wales identi¢ed
between September 1995 and August 1996, found that
while some deaths might be preventable by better pa-
tient management, most are unlikely to be preventable
by currentmanagement practices.
Heterogeneity in themanagement of
patientswith CAP
Unfortunately, several studies show signi¢cantheteroge-
neity in the management of patients with CAP; conse-
quently, the real impact of guidelines on clinical
outcomes can not be ascertained.The median LOS ran-
ged from 5.0 to 9.0 days among a sample of 20 Canadian
hospitals (24).Only 22% of this variation could be attrib-
uted to disease severity or other identi¢able patient or
hospital factors. These results are similar to those re-
ported by Fine et al. (25) who could attribute only 24%
of the variation in LOS at four U.S. hospitals to known
factors. Similarly, important heterogeneity among insti-
tutionswas observed in the duration of intravenous anti-
biotic therapy and adherence to treatment guidelines.
Inconsistencies and delays in the administration of anti-
biotics were documented in the study of Schwartz et al.
(26), who conducted a retrospective analysis of patients
admitted to their hospital with CAP. Although most pa-
tients receivedregimens that included a third-generation
cephalosporin or a b-lactam/b-lactamase inhibitor com-
bination consistent with published guidelines, up to 22%
received erythromycin alone, a regimen with relatively
poor activity against Haemophilus in£uenzae and other
Gram-negative pathogens and that deviates from pub-
lished guidelines.This point is important because it may
have an impact on determining the LOS. Itmust be high-
lighted that longer LOS does not improve medical out-
comes. McCormick et al. (27) have assessed the
variation in LOS for patients with CAP admitted to one
community and three university teaching hospitals in
U.S.A. Adjusted interhospital di¡erences in mean LOS
ranged from 0.9 to 2.3 days.When the risk of eachmedi-
cal outcome was compared between patients admitted
to the hospital with the shortest LOS and those ad-
mitted to longer stay hospitals, therewere no signi¢cant
di¡erences in mortality, hospital readmission, return to
usual activities, or return toworkduring the ¢rst14 days
after discharge, or in themeannumber of pneumonia-re-
lated symptoms 30 days after admission.
These practice variations are surprising for a disease
that is common, has awell-characterizednatural historyand for which e¡ective drug therapies have been identi-
¢ed. The variations probably represent a source of in-
creased cost to hospitals that is not associated with
improved outcomes. Since disease severity or demo-
graphic factors cannot explain thesevariations, themost
likely source is physician behaviour. The di¡erence ap-
proachesbetweenCAPguidelines are a possible explana-
tion of these variations. In fact, presently, a widely
accepted, standardized guideline for the diagnosis and
treatment of CAP is unavailable. This de¢nitely contri-
butes to the large variation in admission rates, use of in-
stitutional resources, and quality of care given to CAP
patients. In any case, Halm et al. (28) have assessed phy-
sicians’ response to implementation of an emergency de-
partment CAP practice guideline and determine if the
guideline changed physicians’ knowledge and attitudes
about pneumonia care. More than 73% of the physicians
reported the guideline as helpful and more than 94%
wanted it to be continued in the future. Most reported
that the guideline would decrease costs and improve
quality without any increase in adverse outcomes. Two
thirds said they were more likely to treat patients with
pneumonia as outpatients in the future because of the
guideline. Among the 58 physicians with matching pre-
intervention and post-inter-vention survey data, the
guideline decreased the beliefs that ‘‘all patients4 65
years old with pneumonia should be admitted’’, from
52% to14%, and that ‘‘patients with pneumonia have a4
15% mortality rate’’, from 11 to 5%.The intervention did
not signi¢cantly change general attitudes about practice
guidelines. House o⁄cers rated the guideline as more
helpful than attending physicians. It seems interesting to
highlight thatrecently Fantin etal. (29) have documented
the discrepancy between the poor adherence of general
practitioners to French recommendations and, overall,
the good outcome of CAPmanagedby the general prac-
titioner. This was mainly due to a good selection of the
patients requiring hospitalization.
The BTS empirical antibiotic recommendation for
non-severe CAP is that oral treatment is usually ade-
quate, and that an aminopenicillin or benzylpenicillin is a
suitable choice (5). However, local guidelines in U.K. fol-
lowed these recommendations in only two-thirds of
cases, the major di¡erence being the recommendation
for dual therapy with a b-lactam plus a macrolide in a
quarter of hospitals. The perception that monotherapy
with an aminopenicillin alone is too narrow-spectrum
or a lack of consensus about what represents severe
CAP are possible explanations for this (30).
CONCLUSION
There is some weak evidence to suggest that, at least in
North America, use of the ATS guidelines and variations
thereof may make a di¡erence, most of all to cost.
210 RESPIRATORYMEDICINEHowever, they should not be over-prescribed, although,
as correctly stressedby Schwartzetal. (26), failure to use
antibiotic regimens recommended in the guidelines may
be associatedwith highermortality rates.
Unfortunately, we do not know yet if the guidelines
for themanagement of CAP have in£uenced outcome in
Europe because, at the moment, there is no European
study that has estimated the impact of the di¡erent na-
tional guidelines on medical outcomes or costs asso-
ciated with the treatment algorithms. It is essential,
therefore, that studies will be designated that will not
be retrospective andwill consider the Europeanpeculia-
rities. In fact, the abilityof guidelines tomake a di¡erence
depends onwhere they start.Theprescriptivebehaviour
of physicians and also the acceptability of the treatments
from patients in Europe are di¡erent from those in
U.S.A. mainly because of the di¡erent health systems.
Obviously, there is the need for more uniform and
consistent antibiotic regimens for CAP. In fact, guidelines
must reevaluate to minimize or eliminate the use of sub-
optimal agents. For example, many clinical treatment
guidelines for empiric therapy for CAP in adults have re-
commended to usemacrolides as ¢rst-line agents.The in-
creasing frequency of macrolide resistance among
pneumococci (31) and increasing MICs among resistant
strains (32) suggest that these treatment recommenda-
tions may need reevaluation. If a pathway or algorithm
o¡ers the clinician a single antimicrobial as ¢rst-line ther-
apy, and resistance to this agent is on the rise, the path-
waymay stopworking.
Treatment guidelines for CAP should be based on the
outcome of a reliable surveillance system. Having local
data onmicrobial andresistancepatternswould improve
the application of guidelines in di¡erent settings.There-
fore, surveillance of bacterial resistance requires a dedi-
cated approach that takes laboratorymethods as well as
epidemiological principles into account. For this reason,
the deploymentof individual drugs anddosages shouldbe
locally decided on the basis of prevailing conditions, and,
moreover, the physician’s assessment of needs of each
case. Another solution is to provide the clinician with
several e¡ective and newer antimicrobial choices; how-
ever, cost-e¡ectiveness of treatment may be compro-
mised.
Fortunately, the recently revisited Infectious Disease
Society of America guidelines (33), and ATS guidelines
(34) incorporate these points and give important sug-
gestions on how to improve our approach to the treat-
ment of CAP. Nonetheless, we believe that use of the
most potent agents available, preferably in bactericidal
synergistic combinations, may be the most e¡ective ac-
tion in preventing in vivo emergence of bacterial resis-
tance. This is an important point considering that the
¢rst-line clinical e¡ectiveness rate is the key cost driver
because of high additional healthcare costs generated by
treatment failure.This is especially the case for those pa-tients with more severe disease because of the greater
probability of hospitalization of such patients following
treatment failure in the community. In any case, regard-
less of which guideline is used to manage pneumonia pa-
tients, there will be some patients who do not respond
appropriately to that guideline.
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